We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · June 07, 2021

HDH Cerebral Embolic Protection Device Is Safe During TAVR

European Heart Journal


Additional Info

European Heart Journal
A Randomized Evaluation of the TriGuard™ HDH Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions After TransCatheter Aortic Valve ImplanTation: The REFLECT I Trial
Eur Heart J 2021 May 17;[EPub Ahead of Print], AJ Lansky, R Makkar, T Nazif, S Messé, J Forrest, R Sharma, J Schofer, A Linke, D Brown, A Dhoble, P Horwitz, M Zang, F DeMarco, V Rajagopal, MG Dwyer, R Zivadinov, P Stella, J Rovin, H Parise, S Kodali, A Baumbach, J Moses

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading